ALR Technologies to Acquire CGM Medical Technology for $45 Million and 200 Million Shares
ALR Technologies has entered into a letter of intent to acquire 100 percent of CGM Medical Technology Singapore and the assets of CGM Medical Technology Shenzhen for a total of 200 million ordinary shares and 45 million US dollars, announced in a press release.
The acquisition will give ALR Technologies full ownership of the intellectual property and technology used in its GluCurve Pet continuous glucose monitor and upcoming human health devices. The company plans to build a manufacturing facility in the Johor-Singapore Special Economic Zone using CGM Medical Singapore’s resources once the deal is completed.
Under the letter of intent, CGM Medical Singapore will be purchased for 200 million shares and a 40 million dollar unsecured, non-interest-bearing promissory note payable through 25 percent of ALR Technologies’ free cash flow after the facility reaches production levels of 500,000 units per month. The Shenzhen assets will be acquired for up to 5 million dollars, with 1 million paid at closing and the remainder through 25 percent of free cash flow once production capacity reaches 300,000 units per month.
ALR Technologies expects to finalize the definitive agreement for CGM Medical Singapore by July 31, 2026, with completion by August 31, 2026. The Shenzhen transaction is expected to close by January 31, 2027, following completion of due diligence, regulatory approvals, and production milestones.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AI Nov 19 Boltz raises $110 million to build AI models for drug designMore from Funding
Nov 20 Protesters rally against Anthropic in New York and San Francisco on its stock market debut Nov 19 Anthropic's IPO could channel about $156 billion to charity, TechCrunch estimates Nov 19 Sierra reportedly in talks to raise at a $30 billion valuation Nov 19 Everful raises $48.5 million to build AI infrastructure for global commerce Nov 19 Spanish fintech Devengo raises €5 million for instant payments and AI agent transactionsAI Funding Brief
AI legal research tools
AI products that research case law and legislation for legal professionals.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Agility Robotics Expects $465 Million Raise as SPAC Merger Nears Close
Singapore Commits S$45 Million to Manufacturing AI Adoption
LG CNS leases all capacity at Jakarta AI data center
Laza Medical raises up to $160 million for cardiac imaging system
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Daily AI Brief: the AI news that matters, in your inbox.